• News
  • Medical

ACOG recommendation of cell-free fetal DNA testing supports Sequenom technology

Two organizations issued a joint opinion on Nov. 20 that recommends that cell-free fetal DNA testing be offered to patients at increased risk of aneuploidy, an abnormal number of chromosomes. San Diego-based Sequenom Inc. (Nasdaq: SQNM), provides that screening in its MaterniT21 PLUS test, which analyzes the relative amount of 21, 18, 13 and Y chromosomal material in cell-free DNA.

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!